Brokerages Set Bruker Corporation (NASDAQ:BRKR) Price Target at $56.64

Bruker Corporation (NASDAQ:BRKR) has received an average recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $56.6429.

A number of research firms recently weighed in on BRKR. Wolfe Research initiated coverage on shares of Bruker in a research report on Monday, June 1st. They issued a “peer perform” rating for the company. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Citigroup lowered their price target on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday, August 5th. Finally, UBS Group set a $60.00 price objective on Bruker in a research note on Wednesday, June 24th.

Bruker Stock Down 0.6%

Bruker stock opened at $59.56 on Thursday. The company has a 50 day moving average of $58.66 and a 200-day moving average of $47.48. The stock has a market capitalization of $9.07 billion, a PE ratio of -85.09, a price-to-earnings-growth ratio of 1.82 and a beta of 1.28. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. Bruker has a twelve month low of $28.53 and a twelve month high of $65.30.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.11. The firm had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the business posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities research analysts anticipate that Bruker will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s payout ratio is -28.57%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans increased its holdings in shares of Bruker by 561.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 179,792 shares of the medical research company’s stock worth $8,470,000 after purchasing an additional 152,603 shares during the period. Hantz Financial Services Inc. raised its holdings in shares of Bruker by 202.7% during the 4th quarter. Hantz Financial Services Inc. now owns 41,306 shares of the medical research company’s stock worth $1,946,000 after buying an additional 27,659 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares during the last quarter. Fifth Third Bancorp lifted its stake in Bruker by 4,058.3% in the 1st quarter. Fifth Third Bancorp now owns 57,135 shares of the medical research company’s stock valued at $2,064,000 after purchasing an additional 55,761 shares during the last quarter. Finally, Amundi lifted its stake in shares of Bruker by 244.2% in the 1st quarter. Amundi now owns 62,611 shares of the medical research company’s stock valued at $2,261,000 after acquiring an additional 44,421 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.